

**BCL9 Antibody (monoclonal) (M01)****Mouse monoclonal antibody raised against a partial recombinant BCL9.****Catalog # AT1286a****Specification**

---

**BCL9 Antibody (monoclonal) (M01) - Product Information**

Application	IF, WB, E
Primary Accession	<a href="#">O00512</a>
Other Accession	<a href="#">NM_004326</a>
Reactivity	Human
Host	mouse
Clonality	Monoclonal
Isotype	IgG1 kappa
Calculated MW	149290

**BCL9 Antibody (monoclonal) (M01) - Additional Information****Gene ID** 607**Other Names**

B-cell CLL/lymphoma 9 protein, B-cell lymphoma 9 protein, Bcl-9, Protein legless homolog, BCL9

**Target/Specificity**

BCL9 (NP\_004317, 1036 a.a. ~ 1135 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.

**Dilution**

WB~~1:500~1000

**Format**

Clear, colorless solution in phosphate buffered saline, pH 7.2 .

**Storage**

Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing.

**Precautions**

BCL9 Antibody (monoclonal) (M01) is for research use only and not for use in diagnostic or therapeutic procedures.


**BCL9 Antibody (monoclonal) (M01) - Protocols**

Provided below are standard protocols that you may find useful for product applications.


- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)

- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)


### **BCL9 Antibody (monoclonal) (M01) - Images**



Immunofluorescence of monoclonal antibody to BCL9 on HeLa cell. [antibody concentration 10 ug/ml]



Antibody Reactive Against Recombinant Protein. Western Blot detection against Immunogen (36.74 KDa) .



Detection limit for recombinant GST tagged BCL9 is approximately 0.03ng/ml as a capture antibody.

### **BCL9 Antibody (monoclonal) (M01) - Background**

BCL9 is associated with B-cell acute lymphoblastic leukemia. It may be a target of translocation in

B-cell malignancies with abnormalities of 1q21. Its function is unknown. The overexpression of BCL9 may be of pathogenic significance in B-cell malignancies.

#### **BCL9 Antibody (monoclonal) (M01) - References**

Allosteric remodelling of the histone H3 binding pocket in the Pygo2 PHD finger triggered by its binding to the B9L/BCL9 co-factor. Miller TC, et al. J Mol Biol, 2010 Sep 3. PMID 20637214. Variation at the NFATC2 Locus Increases the Risk of Thiazolinedione-Induced Edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) Study. Bailey SD, et al. Diabetes Care, 2010 Jul 13. PMID 20628086. Personalized smoking cessation: interactions between nicotine dose, dependence and quit-success genotype score. Rose JE, et al. Mol Med, 2010 Jul-Aug. PMID 20379614. Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip. Talmud PJ, et al. Am J Hum Genet, 2009 Nov. PMID 19913121. BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cells. Mani M, et al. Cancer Res, 2009 Oct 1. PMID 19738061.